<DOC>
	<DOCNO>NCT00655135</DOCNO>
	<brief_summary>The objective study assess safety tolerability LDP-02 patient active Crohn 's disease receiving corticosteroid immunosuppressive , assess ability LDP-02 reduce Crohn 's disease activity , obtain pharmacokinetic ( PK ) pharmacodynamic ( PD ) information LDP-02 patient active Crohn 's disease .</brief_summary>
	<brief_title>Phase 2 Study Safety Efficacy LDP-02 Mildly Moderately Active Crohn 's Patients</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>Age 18 80 , nonhospitalized , male nonpregnant , nonlactating female voluntarily able give inform consent . Crohn 's disease least 6 month ' duration . Endoscopic and/or histopathological and/or radiological documentation consistent Crohn 's disease obtain preferably within 24 month screen . Crohn 's disease involve colon and/or ileum . CDAI score 220 400 ( inclusive ) time Screening visit . The CDAI must remain 220 400 1week Screening period patient eligible . Patients may receive oral topical 5ASA compound provided dosage stable least 14day period Screening visit . Patients maintain 5ASA compound constant dose least Day 57 . Patients evidence current GI infection ( bacterial parasitic ) significant infection within 45 day screen visit . Patients serious underlying disease Crohn 's disease include presence history malignancy ( except basal cell carcinoma ) histological evidence dysplasia . Patients significantly impair liver renal function . This include establish chronic liver disease include hepatitis B C. Patients laboratory abnormality Patients use ethanol consume illicit drug , investigator 's opinion , may interfere compliance study procedure . Patients active psychiatric problem , investigator 's opinion , may interfere compliance study procedure . Patients previously receive currently receive treatment monoclonal antibody . Patients receive investigational therapy , exclude medication define protocol , approve therapy investigational protocol within 30 day prior screen . Patients unable attend study visit comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>